LGM
SAGE

Logos Global Management’s Sage Therapeutics SAGE Stock Holding History

Logos Global Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-250,000
Closed -$15.3M – 64
2020
Q3 		$15.3M Buy
+250,000
New +$12.7M 1.96% 16
2020
Q2 		– Sell
-69,591
Closed -$2M – 60
2020
Q1 		$2M Sell
69,591
-120,559
-63% -$6.98M 0.76% 37
2019
Q4 		$13.7M Buy
+190,150
New +$23.4M 3.38% 13

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Logos Global Management's SAGE Position: Q4 2020 in Review

Logos Global Management sold out of Sage Therapeutics (SAGE) in Q4 2020, closing a stake of 250,000 shares — an estimated $15.3M sold.

Logos Global Management first reported a position in SAGE in Q4 2019 and held it in 3 quarters. The position peaked at $15.3M in Q3 2020. 248 funds tracked by Wall St. Rank hold SAGE as of Q4 2020.

  • Logos Global Management reported no remaining Sage Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Logos Global Management sold 250,000 Sage Therapeutics shares in Q4 2020, an estimated $15.3M.
  • Logos Global Management first reported a position in Sage Therapeutics in Q4 2019 and held it in 3 quarters.
  • Logos Global Management's Sage Therapeutics position peaked at $15.3M in Q3 2020.
  • 248 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2020.

Based on Logos Global Management's 13F filing for Q4 2020, filed 16 Feb 2021.